Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

GTXI $1.13 0.3100 +37.80%
IMMU $2.08 0.2400 +13.04%
JUNO $47.32 3.7300 +8.56%
JUNO $47.32 3.7300 +8.56%
ONCY $0.46 0.0328 +7.63%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NKTR $10.30 -1.1100 -9.73%
EPZM $13.54 -1.4300 -9.55%
INFI $8.04 -0.7950 -9.00%
BLCM $14.49 -1.4000 -8.81%
GHDX $20.78 -1.8900 -8.34%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

'Breakthrough' Drug May Not Mean What You Think

( Sept 22, 2015 - What the Food and Drug Administration calls a 'breakthrough' drug is often not the same as what a layperson would call a breakthrough, a new study shows.
read article 

Goldman Chief Lloyd Blankfein Discloses 'Highly Curable’ Cancer

(Forbes) Sept 22, 2015 - In a memo sent to employees and filed on the SEC’s website, Goldman Sachs chairman and CEO Lloyd Blankfein revealed Tuesday morning that he has a “highly curable” form of lymphoma.
read article 

It Is Time For An Honest Conversation About Money And Cancer

(KevinMD blog) Sept 22, 2015 - There are two, old, particularly nasty rumors, about cash and cancer.
read article 

National Cancer Experience Survey Gives Voice to Patients and Caregivers

(CTCA) Sept 17, 2015 - Insights reveal gaps in cancer care, underscore need for more coordinated care models.
read press release 

Susan G. Komen® 2015 Breast Cancer Research Funding Targets Early-Career Investigators, New Therapies, Health Inequities, and Metastatic Disease

(Susan G. Komen) Sept 22, 2015 - Susan G. Komen, the world’s largest nonprofit funder of breast cancer research, announced new grants to 124 researchers in 25 states and eight countries internationally, with about half of the grants targeted to early-career researchers squeezed by stagnation in federal research dollars.
read press release 

NCI Fields 'Dream Team' for New Pathway-Focused SPORE

(MedPage Today/The Gupta Guide) Sept 21, 2015 - The National Cancer Institute may be taking a page from Stand Up To Cancer's playbook by funding what is tantamount to a Specialized Programs of Research Excellence (SPORE) "dream team.”
read article (free registration required) 

ICON, IBM Partner To Optimize Clinical Trial Outcome

(BioSpectrum) Sept 21, 2015 - ICON is applying Watson Clinical Trial Matching to its breast, lung, colon and rectal cancer trials.
read article 

H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration

(Yahoo! Finance) Sept 22, 2015 - H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita, the largest drug discovery company in Central and Eastern Europe, announced today that they have extended their strategic collaboration to develop breakthrough precision medicines for cancers through September 2016.
read article 

AstraZeneca Taps Crowd Sourcing To Find Cancer Drug Cocktails

(Reuters) Sept 22, 2015 - Drugmaker AstraZeneca is harnessing the wisdom of crowds to help mix tomorrow's cancer drug cocktails.
read article 

2015 Symposium Highlights Notable Advances in Breast Cancer Research

(ASCO) Sept 21, 2015 - Summaries of two notable studies to be presented at the 2015 Breast Cancer Symposium are now available. This will be the final year for the Breast Cancer Symposium, held annually since 2007.
read press release 

ECC 2015 Preview: Scientific Co-chair Peter Naredi, MD, PhD

(Medscape Medical News) Sept 21, 2015 - ECC 2015 Scientific Co-chair Dr Peter Naredi highlights the major themes of the 2015 European Cancer Congress, including the care of elderly cancer patients and the value of patient advocates.
read article (free registration required) 

Cancer Treatment Centers of America at Western Regional Medical Center Launches Next Phase of Immunotherapy Clinical Trial Aimed at Soft-Tissue Cancers

(CTCA) Sept 17, 2015 - New arm of innovative ‘PembroPlus’ clinical trial targets sarcomas.
read press release 

Takeda to Highlight Ixazomib Clinical Development Program at Upcoming International Myeloma Workshop

(StreetInsider) Sept 22, 2015 - Takeda Pharmaceutical Company Limited today announced that it will highlight the ixazomib clinical development program during multiple poster sessions at the upcoming 15th International Myeloma Workshop (IMW 2015) to be held in Rome, Italy, from September 23 to 26, 2015.
read article 

Drug Combination Fights Pancreatic Cancer

(Stanford Medicine) Sept 21, 2015 - A combination of two drugs, one already approved by the Food and Drug Administration, appears to be effective at shrinking pancreatic cancers in laboratory mice, according to a new study by researchers at the Stanford University School of Medicine.
read article 

Relaxed Guidelines on PSA Testing Might Miss Aggressive Tumors: Study

(U.S. News & World Report/HealthDay News) Sept 22, 2015 - Relaxed guidelines on prostate cancer screening may delay diagnosis and treatment of aggressive tumors, a new study suggests.
read article 

Scientists Identify DNA Alterations as Among Earliest to Occur in Lung Cancer Development

(Johns Hopkins) Sept 21, 2015 - Working with tissue, blood and DNA from six people with precancerous and cancerous lung lesions, a team of Johns Hopkins scientists has identified what it believes are among the very earliest “premalignant” genetic changes that mark the potential onset of the most common and deadliest form of disease.
read press release 

Arsenic Trioxide Feasible In Low-, High-Risk Acute Promyelocytic Leukaemia

(medwireNews) Sept 21, 2015 - The use of arsenic trioxide instead of idarubicin in combination with all-trans retinoic acid (ATRA) is a feasible option in patients with acute promyelocytic leukaemia, regardless of risk level, suggests a phase III trial.
read article 

Regorafenib Deemed Not Cost-Effective for Metastatic CRC

(Physician’s Briefing/HealthDay News) Sept 21, 2015 - Given its high cost, regorafenib provides little added benefit as a third-line treatment for metastatic colorectal cancer, according to a study published online Aug. 24 in the Journal of Clinical Oncology.
read article 

Men and Women Face Cancer Differently

(Wall Street Journal) Sept 21, 2015 - Women and men with certain types of cancer appear to take very different approaches in deciding how to treat their disease, a new social-media study from Memorial Sloan Kettering found.
read article (paid subscription required) 

Exclusive: Americans Overpaying Hugely For Cancer Drugs - Academic Study

(Reuters) Sept 22, 2015 - Americans are paying way over the odds for some modern cancer drugs, with pharmaceutical companies charging up to 600 times what the medicines cost to make, according to an independent academic study. The United States also pays more than double the price charged in Europe for these drugs.
read article 

Study: Brentuximab Vedotin Effective, Safe in Elderly Hodgkin Lymphoma Patients Who Cannot Tolerate Standard Chemotherapy

(ASH) Sept 21, 2015 - A study published online in Blood, the Journal of the American Society of Hematology (ASH), reports that bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy.
read press release 

Jury Still Out On E-Cigarettes As Cessation Aid, U.S. Doctors Say

(Reuters Health) Sept 21, 2015 - There isn’t enough evidence yet to say whether e-cigarettes are safe or effective for helping people quit smoking, new U.S. guidelines on tobacco cessation conclude.
read article 

The Utility of Cost Discussions Between Patients With Cancer and Oncologists

( Sept 15, 2015 - Many patients with cancer desire cost discussions with doctors, but those discussions are rare. Nevertheless, cost discussions may lower patient costs—usually without altering treatment.
read article 

Genmab's Arzerra Gets Six-Month Review For Maintenance CLL

(PharmaTimes [UK]) Sept 21, 2015 - Genmab is a giant leap closer to getting its cancer drug Arzerra on the market for maintenance treatment of chronic lymphocytic leukaemia, after US regulators said they would review the application in a speedy six-month timeframe.
read article 

US Priority Review For Amgen's Multiple Myeloma Drug

(PharmaTimes [UK]) Sept 21, 2015 - US regulators will undertake a speedy assessment of Amgen’s request to expand the scope of its cancer jab Kyprolis in patients with relapsed multiple myeloma.
read article